ImmunoGen, Inc. (NASDAQ:IMGN) has received a consensus rating of “Hold” from the eleven brokerages that are covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $7.46.

A number of analysts recently weighed in on IMGN shares. Cowen and Company reaffirmed a “hold” rating on shares of ImmunoGen in a research note on Tuesday, August 29th. William Blair reaffirmed an “outperform” rating on shares of ImmunoGen in a research note on Monday, June 26th. BidaskClub lowered shares of ImmunoGen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Zacks Investment Research raised shares of ImmunoGen from a “hold” rating to a “buy” rating and set a $7.75 price objective for the company in a research note on Tuesday, June 27th. Finally, Cantor Fitzgerald set a $5.00 price objective on shares of ImmunoGen and gave the stock a “hold” rating in a research note on Friday, July 28th.

TRADEMARK VIOLATION WARNING: “Analysts Set ImmunoGen, Inc. (IMGN) Price Target at $7.46” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/analysts-set-immunogen-inc-imgn-price-target-at-7-46/1608563.html.

In other ImmunoGen news, VP Craig Barrows sold 37,050 shares of the business’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $6.81, for a total value of $252,310.50. Following the completion of the transaction, the vice president now directly owns 51,100 shares in the company, valued at $347,991. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.51% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its holdings in ImmunoGen by 37,346.0% in the first quarter. JPMorgan Chase & Co. now owns 187,230 shares of the biotechnology company’s stock worth $725,000 after purchasing an additional 186,730 shares in the last quarter. Stifel Financial Corp raised its holdings in ImmunoGen by 14.2% in the first quarter. Stifel Financial Corp now owns 103,815 shares of the biotechnology company’s stock worth $382,000 after purchasing an additional 12,907 shares in the last quarter. Neuberger Berman Group LLC raised its holdings in ImmunoGen by 8.2% in the first quarter. Neuberger Berman Group LLC now owns 47,943 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 3,616 shares in the last quarter. Geode Capital Management LLC raised its holdings in ImmunoGen by 3.5% in the first quarter. Geode Capital Management LLC now owns 678,343 shares of the biotechnology company’s stock worth $2,625,000 after purchasing an additional 22,991 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in ImmunoGen by 0.7% in the first quarter. Vanguard Group Inc. now owns 4,110,431 shares of the biotechnology company’s stock worth $15,907,000 after purchasing an additional 27,141 shares in the last quarter. Institutional investors and hedge funds own 67.57% of the company’s stock.

Shares of ImmunoGen (NASDAQ:IMGN) traded up 2.35% on Friday, hitting $7.83. 2,053,368 shares of the company traded hands. ImmunoGen has a 1-year low of $1.51 and a 1-year high of $8.84. The firm’s 50-day moving average is $7.01 and its 200 day moving average is $5.51. The firm’s market capitalization is $701.54 million.

ImmunoGen (NASDAQ:IMGN) last released its quarterly earnings data on Friday, July 28th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.07. The business had revenue of $39.02 million during the quarter, compared to analysts’ expectations of $30.59 million. During the same period last year, the company earned ($0.53) earnings per share. The firm’s revenue was up 426.6% compared to the same quarter last year. On average, analysts anticipate that ImmunoGen will post ($0.74) earnings per share for the current fiscal year.

About ImmunoGen

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Analyst Recommendations for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.